...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Intracellular transactivation of epidermal growth factor receptor by α1A-adrenoceptor is mediated by phosphatidylinositol 3-kinase independently of activation of extracellular signal regulated kinases 1/2 and serine-threonine kinases in chinese hamster ovary cells
【24h】

Intracellular transactivation of epidermal growth factor receptor by α1A-adrenoceptor is mediated by phosphatidylinositol 3-kinase independently of activation of extracellular signal regulated kinases 1/2 and serine-threonine kinases in chinese hamster ovary cells

机译:磷脂酰肌醇3-激酶介导α1A-肾上腺素受体对表皮生长因子受体的细胞内反式激活,而与中国仓鼠卵巢细胞中的细胞外信号调节激酶1/2和丝氨酸-苏氨酸激酶的激活无关

获取原文
获取原文并翻译 | 示例
           

摘要

Transactivation of epidermal growth factor receptor (EGFR) by α1-adrenoceptor (α1-AR) is implicated in contraction and hypertrophy of vascular smooth muscle (VSM). We examine whether all α1-AR subtypes transactivate EGFR and explore the mechanism of transactivation. Chinese hamster ovary (CHO) cells stably expressing one subtype of α1-AR were transiently transfected with EGFR. The transactivation mechanism was examined both by coexpression of a chimeric erythropoietin (EPO)-EGFR with an extracellular EPO and intracellular EGFR domain, and by pharmacologic inhibition of external and internal signaling routes. All three α1-AR subtypes transactivated EGFR, which was dependent on the increase in intracellular calcium. The EGFR kinase inhibitor AG1478 [4-(3′-chloroanilino)-6,7-dimethoxyquinazoline] abrogated α1A-AR and α1D-AR induced phosphorylation of EGFR, but both the inhibition of matrix metalloproteinases by GM6001 [(R)-N4-hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoylethyl]-2- isobutyl-succinamide] or blockade of EGFR by cetuximab did not. Stimulation of α1A-AR and α1D-AR also induced phosphorylation of EPO-EGFR chimeric receptors. Moreover, α1A-AR stimulation enhanced phosphorylation of extracellular signal regulated kinase (ERK) 1/2 and serine-threonine kinases (Akt), which were both unaffected by AG1478, indicating that ERK1/2 and Akt phosphorylation is independent of EGFR transactivation. Accordingly, inhibitors of ERK1/2 or Akt did not influence the α1A-AR-mediated EGFR transactivation. Inhibition of calcium/calmodulin-dependent kinase II (CaMKII), phosphatidylinositol 3-kinase (PI3K), and Src, however, did block EGFR transactivation by α 1A-AR and α1D-AR. These findings demonstrate that all α1-AR subtypes transactivate EGFR, which is dependent on an intracellular signaling route involving an increase in calcium and activation of CaMKII, PI3K, and Src, but not the of ERK1/2 and Akt pathways.
机译:α1-肾上腺素能受体(α1-AR)对表皮生长因子受体(EGFR)的反式激活与血管平滑肌(VSM)的收缩和肥大有关。我们检查是否所有α1-AR亚型都激活EGFR,并探讨了激活机制。用EGFR瞬时转染稳定表达一种α1-AR亚型的中国仓鼠卵巢(CHO)细胞。通过嵌合促红细胞生成素(EPO)-EGFR与细胞外EPO和细胞内EGFR域的共表达,以及通过药理作用抑制外部和内部信号传导途径,研究了反式激活机制。所有三种α1-AR亚型都使EGFR活化,这取决于细胞内钙的增加。 EGFR激酶抑制剂AG1478 [4-(3'-chloroanilino)-6,7-二甲氧基喹唑啉]废除了α1A-AR和α1D-AR诱导的EGFR磷酸化,但均被GM6001 [(R)-N4-抑制基质金属蛋白酶羟基-N1-[(S)-2-(1H-吲哚-3-基)-1-甲基氨基甲酰基乙基] -2-异丁基-琥珀酰胺]或西妥昔单抗对EGFR的阻止。刺激α1A-AR和α1D-AR也会诱导EPO-EGFR嵌合受体的磷酸化。此外,α1A-AR刺激增强了不受AG1478影响的细胞外信号调节激酶(ERK)1/2和丝氨酸-苏氨酸激酶(Akt)的磷酸化,表明ERK1 / 2和Akt磷酸化独立于EGFR反式激活。因此,ERK1 / 2或Akt的抑制剂不影响α1A-AR介导的EGFR反式激活。然而,抑制钙/钙调蛋白依赖性激酶II(CaMKII),磷脂酰肌醇3激酶(PI3K)和Src确实阻止了α1A-AR和α1D-AR的EGFR反式激活。这些发现表明,所有α1-AR亚型均能激活EGFR,这取决于细胞内信号传导途径,该途径涉及钙的增加和CaMKII,PI3K和Src的活化,但不依赖于ERK1 / 2和Akt途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号